Weight & Metabolic
Triple-agonist weight loss
A GLP-1, GIP and glucagon triple agonist for significant, sustained weight loss.
Ships as a freeze-dried powder. Need water to mix it? Add Reconstitution Solution.
The science
Evidence level
4/5
Phase 3 trials
Published phase 3 trials support investigational retatrutide; FDA approval and equivalence of this compounded preparation are not established.
25.0%1
average weight loss at 80 weeks on the highest dose, phase 3
86%4
reached normal liver fat by 24 weeks on the top dose, phase 2 substudy
2,3391
adults randomized in the phase 3 obesity trial
Mechanism of action
Targets & pathways
Retatrutide is a single peptide engineered to activate GLP-1, GIP and glucagon receptors; structural studies show how it engages all three5.
Glucagon-receptor activation adds a third metabolic signal with a strong effect on the liver, where fat fell by 82.4% in 24 weeks at the top dose4.
What the research shows
At 80 weeks, the highest dose averaged 25.0% weight reduction versus 3.9% with placebo across 2,339 adults.
Liver fat fell by 82.4% at the top dose, and 86% of participants reached normal levels within 24 weeks.
The phase 2 obesity trial reached 24.2% mean weight loss at 48 weeks, versus 2.1% with placebo.
In type 2 diabetes, the top dose lowered HbA1c by 2.02% at 24 weeks, alongside robust weight reduction.
The 80-week phase 3 obesity trial randomized 2,339 adults; the highest-dose treatment-regimen mean reduction was 25.0% versus 3.9% with placebo.
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.
The New England journal of medicine · 2026
PubMed ↗ (opens in a new tab)A liver-fat substudy found an 82.4% relative reduction at 24 weeks in the highest-dose arm versus a 0.3% increase with placebo.
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Nature medicine · 2024
PubMed ↗ (opens in a new tab)The 338-person obesity trial reported 24.2% highest-dose mean reduction at 48 weeks versus 2.1% with placebo, with gastrointestinal and heart-rate effects.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
The New England journal of medicine · 2023
PubMed ↗ (opens in a new tab)Questions
RT-3 is a triple agonist with published investigational trials. TRZ-2 is tirzepatide, with approved branded dual-agonist preparations; the compounded products do not inherit brand or trial equivalence.
No. Separate trial populations, durations and estimands prevent a valid superiority claim from headline averages alone.
They are different studies with different durations and populations; the newer trial extends, rather than replaces, the earlier evidence.
No. It is the mean in a specific trial arm under the reported analysis approach.
No. A substudy imaging endpoint is not a verified long-term clinical or approved-indication outcome.
Weight & Metabolic
Weight & Metabolic
Weight & Metabolic
Weight & Metabolic